Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
September 2026—From the CAP’s founding nearly 80 years ago, our organization has had a focus that sets us apart from all other pathology societies: our commitment to laboratory quality. Those of us in the U.S. are very familiar with the CAP accreditation process—which is widely considered the gold standard in laboratory accreditation—as the CAP has deemed status to accredit clinical laboratories under the U.S. Clinical Laboratory Improvement Amendments regulations.
September 2026—Three subtypes of inflammatory bowel disease present as chronic inflammation in children and adolescents: ulcerative colitis, Crohn’s disease, and IBD unclassified. The incidence of IBD continues to increase in pediatric populations, with a growing number of cases in preschool children. Familial patterns have been observed in 19 to 41 percent of patients, especially those younger than 11 years of age. The diagnosis of IBD is typically based on clinical presentation, endoscopic evaluation, and histological assessment of intestinal mucosa.
September 2026—Autoimmune atrophic gastritis is chronic, immune-mediated inflammation restricted to the gastric body. Despite well-defined histologic features, its pathologic progression is still not fully understood. Therefore, the authors conducted a study to evaluate the pathologic progression of autoimmune atrophic gastritis. They reviewed cases with at least two follow-up biopsies.
September 2026—HIV remains a major global public health concern, with an estimated 40.8 million people living with the virus in 2024. The challenge is particularly striking in low- and middle-income countries, where access to diagnostic testing may be limited. The World Health Organization’s universal test-and-treat strategy recommends that patients diagnosed with HIV immediately begin antiretroviral therapy regardless of their CD4 cell count or clinical stage. This strategy has placed greater emphasis on routine viral load monitoring, leading to a marked decline in CD4 testing and the discontinuation of many point-of-care CD4 platforms.
September 2026
Q. What is the percent acceptability when conducting a comparison test of activated clotting times (ACT)? Read answer.
Q. Is there any circumstance in which a manual bone marrow differential would be more accurate than flow cytometric analysis? Read answer.
September 2026—Twelve U.S. health systems have joined forces with the clinical artificial intelligence company Aidoc to form the Diagnostic AI Consortium, with the goal of harnessing AI to improve the safety, quality, and speed of patient diagnosis and developing and adhering to standards for evaluating and governing the capability.
September 2026—A federal appeals court struck down portions of the federal regulations governing the calculation of the qualifying payment amount (QPA) under the No Surprises Act. The U.S. Court of Appeals for the Fifth Circuit, sitting en banc, issued its decision Aug. 11 in Texas Medical Association v. United States Department of Health and Human Services. The QPA is an insurer-calculated figure that is an important element in independent dispute resolution proceedings in which the amount an insurer owes to an out-of-network provider is adjudicated.
August 2026—At the upcoming CAP26 annual meeting in Las Vegas, you might notice key differences compared with our past meetings. We know some elements that were once compelling reasons to attend conferences, such as CME credits, are no longer the draw they used to be.
August 2026—Patients undergoing cardiac surgery have a higher risk of excessive bleeding and complications due to dilutional effects during surgery and activation and consumption of platelets and coagulation factors. Increasing recognition of the related morbidity and mortality has heightened interest in patient blood management, including autologous blood salvage (ABS) using an automated cell-salvage system for safe and effective blood conservation in cardiac surgery with cardiopulmonary bypass. Of importance in adult and pediatric populations is that reinfused washed red blood cells be of high quality to prevent adverse events from cytolysis and activation processes and severe and fatal complications.
August 2026—Primary perianal adenocarcinoma of intestinal type has been described in recent literature and proposed as a subtype of extramucosal anal adenocarcinoma. Whether this represents a unique entity remains to be elucidated. The authors conducted a study in which they analyzed the clinicopathologic and genomic features of 14 cases of primary perianal adenocarcinoma of intestinal type (PPAI).
